Byterna is a biopharmaceutical company based in Shanghai, China,
that focuses on circular mRNA (cmRNA) therapeutics, primarily in vivo cmRNA CAR-T cell therapy. We leverage artificial intelligence (AI) to accelerate cmRNA design, and targeted lipid nanoparticles (LNP) to deliver cmRNA cargo into T cells to generate CAR-T cells within the body.

Powered by our innovative cmRNA and LNP platforms, we are developing a novel class of cmRNA therapeutics to achieve "Safe, Effective, Accessible, Affordable (SEAA)" CAR-based cell therapies for global patients.